Sex: F
Vaccine: COVID19
Symptoms: Antibody test, SARS-CoV-2 test, Skin cancer
Clinical narrative: skin cancer; This is a spontaneous report received from a contactable reporter(s) (Other HCP) from medical information team.  A 70 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "bladder cancer", start date: 2021 (unspecified if ongoing), notes: has diagnosed bladder cancer in 2021, received treatment in 2022; "open heart surgery", start date: 2015 (unspecified if ongoing); "stroke" (unspecified if ongoing); "Sick", start date: Mar2020 (unspecified if ongoing); "overweight" (unspecified if ongoing); "has an enlarged heart" (unspecified if ongoing); "hip replacement, carpal tunnel" (unspecified if ongoing); "hip replacement" (unspecified if ongoing); "could not speak, aphasic, I was not able to find the right words" (unspecified if ongoing); "heart not like supposed be" (ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose 1, single), for COVID-19 Immunization; Bnt162b2 (dose 2, single), for COVID-19 Immunization. The following information was reported: SKIN CANCER (medically significant) with onset 2022, outcome "unknown", described as "skin cancer". The patient underwent the following laboratory tests and procedures: antibody test: none, zero, notes: her doctor checked for antibodies and she has "none, zero"; sars-cov-2 test: negative, notes: was tested multiple times since then and always with negative results. Clinical course: The nurse was seeking information regarding antibody testing after receiving three doses of Pfizer Covid vaccine. The female patient stated that her doctor checked for antibodies and she has "none, zero". The patient was diagnosed with bladder cancer in 2021, received treatment in 2022, now diagnosed with skin cancer. She states she is overweight and has an enlarged heart. The patient stated, "I had both hip replacement, carpal tunnel and open heart surgery in 2015. I had stroke, could not speak, aphasic, I was not able to find the right words but with hard work I did recuperate, not completely, I still have a hard time with the words, my speech was not garbled. I did not have any physical weakness. Still high risk of stroke and my heart not like supposed be." The patient was sick in Mar2020 but was not tested for Covid at that time. She was tested multiple times since then and always with negative results. The patient stated, " I heard 7 million people who did receive that don't show antibody protection. What kind of test should I get?". The nurse asked, "How they do get those results of "98% protection after vaccination" and stated, "and also what I was worried about this my zero no vaccination antibody, I was looking at the internet and I came that protein what we have in our bodies, I don't remember what kind, preventing immune system from having antibody. When I was looking for that, I found out about the disease of heart they called attr-cm and involved the protein what makes the heart growing the muscle of the heart growing bigger and getting the heart condition what I have then. I'm wondering if this connected with the protein the immune system from having antibody response? According to the article, the heart condition people have shortness of breath swelling elevated blood pressure bilateral hip replacement carpal tunnel. All those symptoms what I had - prevention for those?" Asking if this same protein affects the immune system.  The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Based on the information provide and plausible temporal association, the causality between BNT162B2 and SKIN CANCER cannot be completely excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.